title: The association of receptor of advanced glycated end products and inflammatory mediators contributes to endothelial dysfunction in a prospective study of acute kidney injury patients with sepsis.
abstract: The pathogenesis of acute kidney injury (AKI) occurring due to sepsis is incompletely understood. Endothelial activation, defined as up-regulation of adhesion molecules by proinflammatory cytokines, may be central to the development of sepsis-induced AKI. Our aim was to determine levels of circulating adhesion molecules endothelial (E)-selectin, intercellular adhesion molecule (ICAM), and vascular cell adhesion molecule (VCAM), inflammatory mediators; tumor necrosis factor-α (TNF-α) and transforming growth factor-β (TGF-β), vasoactive mediators; endothelin-1 (ET-1) and nitric oxide (NO), soluble receptor for advanced glycated end products (sRAGE) and serum fetuin-A in septic AKI patients before and after antibiotic therapy. Nineteen AKI patients with sepsis and fifteen healthy controls were enrolled in this prospective study. Results revealed that 12 weeks of therapy caused amelioration of endothelial and inflammatory injuries as well as renal function markers. Moreover, the positive correlations between levels of RAGE and E-selectin (r=0.88), ET-1 (r=0.90), and TNF-α (r=0.94) and negative with NO (r=-0.75-0.95) suggest that possible interaction of RAGE and inflammation may contribute to endothelial dysfunction in septic AKI patients.
authors.affiliation: Faculty of Pharmacy, Biochemistry Department, Cairo University, Kasr El-Eini Street, Cairo, 11562, Egypt. nerminsadik@yahoo.com
authors.forename: Nermin A H
authors.initials: NA
authors.lastname: Sadik
authors.forename: Waleed A
authors.initials: WA
authors.lastname: Mohamed
authors.forename: Mohamed I
authors.initials: MI
authors.lastname: Ahmed
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D004730:Endothelium, Vascular / Q000187:drug effects / Q000503:physiopathology*; D005260:Female; D017127:Glycation End Products, Advanced; D006801:Humans; D007249:Inflammation / Q000150:complications / Q000188:drug therapy; D018836:Inflammation Mediators; D007674:Kidney Diseases / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018805:Sepsis / Q000150:complications* / Q000188:drug therapy / Q000473:pathology
chemical_list: D000900:Anti-Bacterial Agents; D017127:Glycation End Products, Advanced; D018836:Inflammation Mediators